BRPI0509559A - compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos - Google Patents

compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos

Info

Publication number
BRPI0509559A
BRPI0509559A BRPI0509559-0A BRPI0509559A BRPI0509559A BR PI0509559 A BRPI0509559 A BR PI0509559A BR PI0509559 A BRPI0509559 A BR PI0509559A BR PI0509559 A BRPI0509559 A BR PI0509559A
Authority
BR
Brazil
Prior art keywords
compounds
pyrazolamine
treatment
neurodegenerative disorders
formula
Prior art date
Application number
BRPI0509559-0A
Other languages
English (en)
Inventor
Yuhpyng L Chen
Lei Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0509559A publication Critical patent/BRPI0509559A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPOSTOS DE PIRAZOLAMINA PARA O TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS. A presente invenção refere-se a compostos de fórmula: em que R¬ 1¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 7¬ e R¬ 8¬ são como definidos acima. Os compostos de fórmula (I) apresentam atividade quando da produção de inibição de A<225>-peptídeos. A invenção também refere-se a composições farmacêuticas e a métodos de tratamento de distúrbios e doenças, por exemplo, doença de Alzheimer, em um mamífero, compreendendo os compostos de fórmula (I).
BRPI0509559-0A 2004-04-01 2005-03-21 compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos BRPI0509559A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55890404P 2004-04-01 2004-04-01
PCT/IB2005/000793 WO2005095348A2 (en) 2004-04-01 2005-03-21 Pyrazole-amine compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0509559A true BRPI0509559A (pt) 2007-09-18

Family

ID=34962302

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509559-0A BRPI0509559A (pt) 2004-04-01 2005-03-21 compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos

Country Status (10)

Country Link
US (2) US7244757B2 (pt)
EP (2) EP1735285B1 (pt)
JP (1) JP2007530659A (pt)
AT (1) ATE402150T1 (pt)
BR (1) BRPI0509559A (pt)
CA (1) CA2561441A1 (pt)
DE (1) DE602005008417D1 (pt)
ES (1) ES2308442T3 (pt)
MX (1) MXPA06011351A (pt)
WO (1) WO2005095348A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7244757B2 (en) * 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
WO2013178821A1 (en) * 2012-06-01 2013-12-05 Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (FLI) Inhibitors of the notch signalling pathway and secretion for use in medicine
EP3363800A1 (en) 2013-10-03 2018-08-22 Kura Oncology, Inc. Heterocyclic inhibitors of erk and methods of use
TW202000658A (zh) * 2018-02-16 2020-01-01 美商星座製藥公司 P300/cbp hat 抑制劑及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503340Y2 (pt) * 1971-06-17 1975-01-28
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
CN1518543A (zh) 2000-08-31 2004-08-04 �Ʒ� 吡唑衍生物和它们作为蛋白激酶抑制剂的用途
US20040019046A1 (en) 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
WO2003064396A1 (en) 2002-02-01 2003-08-07 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds
AU2003229024A1 (en) 2002-05-07 2003-11-11 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
EP1551809A1 (en) 2002-10-09 2005-07-13 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
CA2524511A1 (en) 2003-05-12 2004-11-18 Pfizer Products Inc. Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
EP1633350B1 (en) * 2003-06-05 2012-10-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
US7244757B2 (en) * 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
EP1958939A3 (en) 2008-09-10
US7244757B2 (en) 2007-07-17
CA2561441A1 (en) 2005-10-13
ATE402150T1 (de) 2008-08-15
EP1958939A2 (en) 2008-08-20
JP2007530659A (ja) 2007-11-01
EP1735285B1 (en) 2008-07-23
ES2308442T3 (es) 2008-12-01
EP1735285A2 (en) 2006-12-27
US20050222239A1 (en) 2005-10-06
WO2005095348A2 (en) 2005-10-13
DE602005008417D1 (de) 2008-09-04
MXPA06011351A (es) 2006-12-15
WO2005095348A3 (en) 2006-03-23
US7468386B2 (en) 2008-12-23
US20070265327A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
UY28817A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegerativos
MY136718A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0509504A (pt) compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
WO2005097114A3 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
BRPI0509582A (pt) compostos de tiazol-amina e respectivas composições farmacêuticas
TW200510351A (en) Oxazole compounds for the treatment of neurodegenerative disorders
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
MY145068A (en) Imidazole compounds for the treatment of neurodegenerative disorders
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
EA200500382A1 (ru) Соединения тиазола для лечения нейродегенеративных расстройств
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2137 DE 20/12/2011.